Search by Journal
- HOME
- > Search by Journal
- > International Journal of Myeloma
International Journal of Myeloma
Volume , Issue suppl / 2011
English Article 
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
It is so a greeting of the - Chairperson greetings opening of a meeting an aim for healing in the integration of dispatch - basics myeloma disease studies and the clinical myeloma disease studies of the global frontier from the 36th Japan myeloma meeting for the study general meeting Japan 三輪哲義 International Journal of Myeloma (suppl): 3-3, 2011. |
|---|
|
multiple myeloma in advanced stage - an infiltrative disease into various organs - Akiyoshi Miwa International Journal of Myeloma (suppl): 32-32, 2011. |
|---|
|
|
L1 How to Treat Complications of Myeloma in the Era of Novel Agents ? Focus on Bone Disease and Renal Impairment Meletios A.Dimopoulos International Journal of Myeloma (suppl): 33-33, 2011. |
|---|
|
|
L2 Oncogenomics in multiple myeloma : Understanding the basic biology to clinical translation Nikhil C.Munshi International Journal of Myeloma (suppl): 34-34, 2011. |
|---|
|
|
L3 Transplantation and cell therapy in the era of novel agents Gosta Gahrton International Journal of Myeloma (suppl): 35-35, 2011. |
|---|
|
|
E1 Novel aspects of proteasome inhibitors Irene M.Ghobrial International Journal of Myeloma (suppl): 36-36, 2011. |
|---|
|
|
The effectiveness of the salvage chemotherapy at the autologous peripheral blood stem cell transplantation for patients with S12-1 symptom-related multiple myeloma and safe examination (JMSG -0901) 吉田喬1, 松本守生2, 角南一貴3, 彼谷裕康4, 島崎千尋5, 黒田純也6, 瀧澤淳7, 五十嵐忠彦8, 村山徹9, 清水一之10 International Journal of Myeloma (suppl): 38-38, 2011. |
|---|
|
|
weekly bortezomib + dexamethasone therapy (JMSG-0902) for S12-2 elderly people recurrence, the intractable multiple myeloma 尾崎修治1, 畑裕之2, 安倍正博3, 斉藤貴之4, 花村一朗5, 矢野寛樹6 International Journal of Myeloma (suppl): 39-39, 2011. |
|---|
|
|
Maintenance therapy phase II study by bortezomib after the allograft using the dose weight loss pre-treatment for S12-3 recurrence, the intractable multiple myeloma 中世古知昭 International Journal of Myeloma (suppl): 40-40, 2011. |
|---|
|
|
The myeloma cells become the fulminant form by S1-1 B7-H1 expression more. 田村秀人1, 石橋真理子1, 山下泰史1, 近藤麻加1, 奥山奈美子1, 兵働英也1, 浜田泰子1, 亀井直樹1, 檀和夫1, Chen, Lieping2, 緒方清行1 International Journal of Myeloma (suppl): 42-42, 2011. |
|---|
|
|
It is a poor prognostic factor, and the CD138 drop of S1-2 myeloma cells is associated with difference in degree of differentiation 河野和1, 藤原志保1, 幸宏道1, 立津央1, 山崎浩2, 坂井晃3, 奥野豊1, 満屋裕明1, 畑裕之1 International Journal of Myeloma (suppl): 43-43, 2011. |
|---|
|
|
The S1-3 Interleukin-10 (IL-10) polymorphic high production type makes multiple myeloma progress 高荷智紀1, 斉藤貴之2,3, 森山紀彦1, 牛江千明1, 星野巧臣3, 三井健揮3, 小磯博美2,3, 横濱章彦4, 半田寛3, 塚本憲史2,3, 澤村守夫5, 小河原はつ江1, 村上博和1 International Journal of Myeloma (suppl): 44-44, 2011. |
|---|
|
|
Inspection of the optimization of the electroporation condition using the S1-4 blood-forming organ tumor cell line 室橋郁生1, 井原寛子2, 中村裕一3 International Journal of Myeloma (suppl): 45-45, 2011. |
|---|
|
|
Mutation in the myeloma of S1-5 Common fragile site gene FHIT and WWOX 半田寛1, 佐々木佳子2, 高橋紀行2, 服部光2, 斉藤貴之4, 小磯博美4, 横濱章彦5, 塚本憲史4, 松本守生3, 磯田淳3, 澤村守夫3, 三井健揮1, 大崎洋平1, 村上博和2 International Journal of Myeloma (suppl): 46-46, 2011. |
|---|
|
|
Serum miR-92a in the S1-6 multiple myeloma reflects peripheral T-cell origin miR-92a 吉澤成一郎1, 大屋敷純子2, 大屋敷倫代1, 藤本博昭1, 後藤守孝1, 後藤明彦1, 北原俊彦1, 岩淵多光子1, 小林千晶1, 廣田綾子1, 大屋敷一馬1 International Journal of Myeloma (suppl): 47-47, 2011. |
|---|
|
|
New proteasome inhibitor oral medication with the S2-1 antimyeloma effect 菊池次郎1, 山田悟史1, 和田妙子1, 信吉正治1, 和泉透2, 阿久津美百生2, 加納康彦2, 古川雄祐1 International Journal of Myeloma (suppl): 48-48, 2011. |
|---|
|
|
Antimyeloma cells effect of the human T cell which produced S2-2 antiCD38 chimera type receptor 三原圭一朗1, バタチャリーアジョイータ1, 北中明2, 井原章裕3, 坂井晃1, 黒田芳明1, 麻奥英毅4, 瀧原義宏5, 木村昭郎1 International Journal of Myeloma (suppl): 49-49, 2011. |
|---|
|
|
Inhibition of conquest and the bony lesion formation of the myeloma drug resistance that acid environment by S2-3 sweeper streptomycin A brings 渡邉佳一郎1,2, 安倍正博1, 崔衢1, 日浅雅博1,2,3, 川谷誠4, 原田武志1, 藤井志朗1, 中村信元1, 三木浩一1, 中野綾子1, 賀川久美子1, 竹内恭子1, 長田裕之4, 田中栄二2, 松本俊夫1 International Journal of Myeloma (suppl): 50-50, 2011. |
|---|
|
|
The antimyeloma effect of the S2-4 Pim inhibitor: The reinforcement of the anti-tumor activity in the acid environment 藤井志朗1, 安倍正博1, 三木浩和1, 原田武志1, 中村信元1, 中野綾子1, 賀川久美子1, 竹内恭子1, 尾崎修治2, 松本俊夫1 International Journal of Myeloma (suppl): 51-51, 2011. |
|---|
|
|
Clinical significance of CD56 (NCAM) in S3-1 multiple myeloma and AL amyloidosis 宮崎寛至, 西山小百合, 吉識由美子, 阿部有, 日下さやか, 関根理恵子, 中川靖章, 鈴木憲史 International Journal of Myeloma (suppl): 52-52, 2011. |
|---|
|
|
One case of the nonsecretor plasmacytic leukaemia treated effectively with S3-2 bortezomib + dexamethasone therapy 武政佑香, 伊藤薫樹, 小宅達郎, 菅原教史, 土居雅宗, 鈴木雄造, 青木有正, 古和田周吾, 菅原健, 村井一範, 石田陽治 International Journal of Myeloma (suppl): 53-53, 2011. |
|---|
|
|
Both the S3-3 multiple myeloma and the plasmacytic leukaemia show approximately equivalent organ abusive moisture at the autopsy 高野淳一朗, 佐藤淳至, 北原英晃, 木村悠子, 塚本彩人, 平井理泉, 谷村聡, 中村美紀, 竹下昌孝, 萩原將太郎, 三輪哲義 International Journal of Myeloma (suppl): 54-54, 2011. |
|---|
|
|
Participation of PVT1 in the multiple myeloma with the S4-1 8q24 abnormality and identification of new chimeric gene PVT1-NBEA 名越久朗1,2, 滝智彦2, 花村一朗3, 仁田正和3, 大槻剛巳4, 西田一弘1, 奥田恵子2, 小林覚1, 山本未央1, 堤康彦1, 古林勉1, 松本洋典1, 堀池重夫1, 黒田純也1, 谷脇雅史1,2 International Journal of Myeloma (suppl): 55-55, 2011. |
|---|
|
|
The detection of the Bence Jones protein in the non-oligohydruria by S4-2 immunity anchorage system Hydrasys 老沼弘俊, 山田俊幸 International Journal of Myeloma (suppl): 56-56, 2011. |
|---|
|
|
Analysis and the effectiveness of the plasma cell-related disease using the S4-3-free light serum free light chain analysis 池田博, 青木由佳, 安井寛, 林敏昭, 石田禎夫, 篠村恭久 International Journal of Myeloma (suppl): 57-57, 2011. |
|---|
|
|
Change of the serum isolation light chain in patients with multiple myeloma during S4-4 bortezomib dexamethasone (BD) therapy 淵田真一1, 岡野晃1, 初瀬真弓1, 村頭智1, 春山春枝1, 伊藤早織2, 島崎千尋1 International Journal of Myeloma (suppl): 58-58, 2011. |
|---|
|
|
Examination of the evaluation method of the form and essence cell count in the S4-5 viewing method, flow cytometry, bone cerebral fluid by the marrow clot immunity banding 鵜飼知嵩, 岩間幹一, 山倉昌之, 竹内正美, 末永孝生 International Journal of Myeloma (suppl): 59-59, 2011. |
|---|
|
|
Inspection of the clinical significance of the D/S PLUS staging using the examination of PET in the S5-1 multiple myeloma 小杉浩史 International Journal of Myeloma (suppl): 60-60, 2011. |
|---|
|
|
Comparison of the video diagnosis of the FDG-PET, methionine PET thymidine PET of the S5-2 multiple myeloma 岡崎百子1, 窪田和雄1, 諸岡都1, 南本亮吾1, 伊藤公輝1, 三輪哲義2 International Journal of Myeloma (suppl): 61-61, 2011. |
|---|
|
|
Evaluation of the myeloma lesion using the S5-3 dynamic contrasting MRI 磯田淳1, 氏田万寿夫2, 馬渡桃子1, 宮澤悠里1, 松本守生1, 松浦正名2, 澤村守夫1 International Journal of Myeloma (suppl): 62-62, 2011. |
|---|
|
|
General image evaluation for the S5-4 multiple myeloma 佐藤淳至, 高野淳一朗, 北原英晃, 木村悠子, 塚本彩人, 平井理泉, 谷村聡, 中村美紀, 竹下昌孝, 萩原將太郎, 三輪哲義 International Journal of Myeloma (suppl): 63-63, 2011. |
|---|
|
|
We see it, and the multicenter rear of the lenalidomide + dexamethasone therapy for patients with intractable multiple myeloma studies a mark S6-1 recurrence 澤崎愛子1, 吉田明2, 福島俊洋3, 高松博幸4, 村田了一5, 奥村廣和6, 神谷健一7, 又野禎也8, 羽場利博9, 中尾眞二4, 杉山敏郎10, 梅原久範3, 上田孝典2 International Journal of Myeloma (suppl): 64-64, 2011. |
|---|
|
|
The IgG - lambda type myeloma that we were able to introduce into CR by maintenance therapy with low-dose lenalidomide after S6-2 autologous peripheral blood stem cell transplantation 石井敬1, 関口直宏1, 竹迫直樹1, 永田明久1, 能登俊1, 三輪哲義2 International Journal of Myeloma (suppl): 65-65, 2011. |
|---|
|
|
The effect that lenalidomide gives to S6-3 self peripheral blood stem cell sampling 横山寿行1, 井根省二2, 遠宮靖雄2, 藤原実名美1, 猪俣美津恵1, 原崎頼子2, 伊藤俊広1, 佐々木治2, 目黒邦昭1, 張替秀郎3 International Journal of Myeloma (suppl): 66-66, 2011. |
|---|
|
|
Examination of the Revlimid treatment result for 41 S6-4 recurrent intractable multiple myeloma 黒田芳明, 坂井晃, 兵頭英出夫, 木村昭郎 International Journal of Myeloma (suppl): 67-67, 2011. |
|---|
|
|
We look at the rear of S6-5 recurrence, 21 cases that gave thalidomide + dexamethasone therapy for intractable myeloma and examine a mark 和泉透, 菊池裕二, 田中勝, 阿久津美百生, 加納康彦 International Journal of Myeloma (suppl): 68-68, 2011. |
|---|
|
|
The effectiveness of the Lenalidomide + dexamethasone (Rd) therapy for S6-6 recurrence, the treatment-resistant multiple myeloma and safe examination 松本守生, 馬渡桃子, 宮澤悠里, 磯田淳, 澤村守夫 International Journal of Myeloma (suppl): 69-69, 2011. |
|---|
|
|
Treatment with Revlimid for a recurrence, the intractable myeloma in our S6-7 institution 今村理恵, 野村桂, 中村剛之, 武田治美, 森重聡, 奥英二郎, 高田由香, 毛利文彦, 橋口道俊, 関律子, 大崎浩一, 水野晋一, 吉本幸治, 長藤宏司, 岡村孝 International Journal of Myeloma (suppl): 70-70, 2011. |
|---|
|
|
Effect of the bortezomib on recurrence, intractable myeloma with the S7-1 poor prognosis chromosome aberration 黒田純也1, 古林勉1, 清田実希1, 山本未央1, 大城宗生1, 志村勇司1, 名越久郎1, 中山理祐子1, 淵田真一2, 内山人二1, 松本洋典1, 島崎千尋2, 堀池重夫1, 谷脇雅史1 International Journal of Myeloma (suppl): 71-71, 2011. |
|---|
|
|
bortezomib subcutaneous administration for patients with S7-2 multiple myeloma 上村智彦1, 鄭湧1, 伊藤能清1, 宮本敏浩2 International Journal of Myeloma (suppl): 72-72, 2011. |
|---|
|
|
Dexamethasone (iPAD) therapy first / II aspect study equivalent among bortezomib, doxorubicin for S7-3 recurrence, the progress-related myeloma 高松泰1, 角南一貴2, 牟田毅3, 塚田順一4, 宮本敏浩5, 衛藤徹也6, 樋口雅一7, 崔日承8, 畑裕之9, 魚住公治10, 田村和夫1 International Journal of Myeloma (suppl): 73-73, 2011. |
|---|
|
|
Histories of treatment of the bell Quaid once a week administration for patients with S7-4 multiple myeloma and oral endoxan and the dexamethasone combination therapy 八木秀男, 佐野圭吾, 藤田茉莉子, 飯塚隆史, 山崎佳子, 花本仁, 椿和央 International Journal of Myeloma (suppl): 74-74, 2011. |
|---|
|
|
A specific use results investigation of S7-5 multiple myeloma therapeutic drug bell Quaid: Report of the last analysis results 村元正和1, 大橋渉2, 野口三規子3, 宮尾真喜子4, 向井陽美1 International Journal of Myeloma (suppl): 75-75, 2011. |
|---|
|
|
Treatment examination of patients with untreated multiple myeloma using the S7-6 new drug 板垣充弘1, 麻奥英毅2, 岡谷健史1, 今中亮太1, 許鴻平1, 片山雄太1, 岩戸康治3, 許泰一1 International Journal of Myeloma (suppl): 76-76, 2011. |
|---|
|
|
Examination of a recurrence, the intractable multiple myeloma case that chronically administered S7-7 bortezomib 中村裕一, 脇本直樹, 伊藤善啓, 別所正美 International Journal of Myeloma (suppl): 77-77, 2011. |
|---|
|
|
Questionnaire findings about the AL amyloidosis practice in S8-1 Hokkaido 林敏昭1, 酒井基2, 進藤基博3, 幸田久平4, 山本聡5, 三宅高義6, 前森雅世2, 池田博1, 野島正寛1, 安井寛1, 石田禎夫1, 篠村恭久1, 福原敬7, 北海道血液症例検討会 International Journal of Myeloma (suppl): 78-78, 2011. |
|---|
|
|
The thalidomide treatment is effective for S8-2 POEMS (Crow-Fukase) syndrome 三澤園子1, 澁谷和幹1, 那須彩子1, 磯瀬沙希里1, 関口縁1, 三津間さつき1, 別府美奈子1, 金井数明1, 武内正博2, 大和田千桂子2, 中世古知昭2, 桑原聡1 International Journal of Myeloma (suppl): 79-79, 2011. |
|---|
|
|
POEMS syndrome recurrent after ASCT which fluid retention improved by S8-3 Lenalidomide + DEX therapy rapidly 大橋晃太, 横山明弘, 籠尾壽哉, 相馬俊介, 細田亮, 朴載源, 上野博則, 矢野尊啓 International Journal of Myeloma (suppl): 80-80, 2011. |
|---|
|
|
An example of the POEMS syndrome which significant pulmonary hypertension improved by S8-4 autologous peripheral blood stem cell transplantation 中世古知昭1, 清水直美2, 大和田千桂子1, 武内正博1, 竹田勇輔1, 酒井紫緒2, 塚本祥吉1, 川口岳晴1, 堺田恵美子1, 井関徹2, 金井数明3, 三澤園子3, 桑原聡3 International Journal of Myeloma (suppl): 81-81, 2011. |
|---|
|
|
Usefulness of the visible symptom evaluation of peripheral neuropathy (PN) by the S9-1 bortezomib 水上久美子1, 久保江利佳1, 山倉昌之2, 秋葉一枝1, 大沼洋子1, 末永孝生2 International Journal of Myeloma (suppl): 82-82, 2011. |
|---|
|
|
The effectiveness of the three-drug antiemesis therapy at the self-peripheral blood stem cell transplantation combination salvage chemotherapy in the S9-2 multiple myeloma and safe examination 眞中章弘1, 磯田淳2, 馬渡桃子2, 宮澤悠里2, 松本守生2, 細川舞3, 澤村守夫2, 佐橋幸子1 International Journal of Myeloma (suppl): 83-83, 2011. |
|---|
|
|
An effect of the treatment with lenalidomide in 22 S9-3 multiple myeloma and safe examination 伊藤薫樹1, 峯貴浩2, 藤島行輝2, 菅原教史1, 武政佑香1, 土居雅宗1, 鈴木雄造1, 岡野良昭3, 筑紫泰彦1, 古和田周吾1, 小宅達郎1, 菅原健1, 村井一範1, 石田陽治1 International Journal of Myeloma (suppl): 84-84, 2011. |
|---|
|
|
Look at peripheral neuropathy ... single institution rear in S9-4 multiple myeloma treatment; mark analysis ... 川上公宏1, 宮川真澄2, 松岡亮仁1, 脇正人1 International Journal of Myeloma (suppl): 85-85, 2011. |
|---|
|
|
Examination of the treatment result of the multiple myeloma in S10-1 Tokushima 原田武志1, 尾崎修治3, 藤井志朗1, 中村信元1, 三木浩和1, 中野綾子1, 賀川久美子1, 竹内恭子2, 安倍正博1, 柴田泰伸3, 重清俊雄3, 橋本年弘4, 武市俊彰5, 篠原正幸6, 松本俊夫1 International Journal of Myeloma (suppl): 86-86, 2011. |
|---|
|
|
Examination of the effectiveness of the relief chemotherapy of patients with myeloma recurrent after S10-2 hematopoietic stem cell transplantation combination salvage chemotherapy 井本直人, 村瀬篤史, 兼松毅, 弓削征章, 小杉浩史 International Journal of Myeloma (suppl): 87-87, 2011. |
|---|
|
|
Middle equal amount melphalan IV therapy for the S10-3 multiple drug refractoriness multiple myeloma 平井理泉, 佐藤淳至, 高野淳一朗, 塚本彩人, 北原英晃, 木村悠子, 谷村聡, 中村美紀, 竹下昌孝, 萩原將太郎, 三輪哲義 International Journal of Myeloma (suppl): 88-88, 2011. |
|---|
|
|
Comparison between a large quantity of cyclophosphamide + G-CSF and hematopoietic cells mobilization regimen by G-CSF alone in the S11-1 multiple myeloma 谷村聡, 竹下昌孝, 佐藤淳至, 高野淳一郎, 北原英晃, 塚本彩人, 木村悠子, 平井理泉, 中村美紀, 萩原將太郎, 三輪哲義 International Journal of Myeloma (suppl): 89-89, 2011. |
|---|
|
|
Outcome improvement of recipients of hematopoietic cells by the S11-2 multidirectional approach 萩原將太郎, 佐藤淳至, 高野淳一朗, 北原英晃, 木村悠子, 塚本彩人, 中村美紀, 平井理泉, 谷村聡, 竹下昌孝, 三輪哲義 International Journal of Myeloma (suppl): 90-90, 2011. |
|---|
|
|
The effectiveness of bortezomib, dexamethasone as the peripheral blood stem cell transplantation pre-treatment for patients with S11-3 youth Japanese multiple myeloma and the high-dose melphalan combination therapy and safety 竹迫直樹1,2, 関口直宏1, 永田明久1, 本間千帆1, 能登俊1, 三輪哲義3 International Journal of Myeloma (suppl): 91-91, 2011. |
|---|
|
|
Examination of the allogeneic hematopoietic stem cell transplantation for the multiple myeloma in the S11-4 our hospital 森甚一, 大橋一輝, 村田裕人, 本田晃, 青木淳, 五十嵐愛子, 葉名尻良, 小林武, 垣花和彦, 坂巻壽 International Journal of Myeloma (suppl): 92-92, 2011. |
|---|
|
|
We look at the rear of 16 cases given allogeneic hematopoietic stem cell transplantation for S11-5 multiple myeloma and examine a mark 田村志宣1, 畑中一生1,2, 栗山幸大1, 細井裕樹1, 村田祥吾1, 島貫栄弥1, 花岡佳伸1, 園木孝志1, 米谷昇3, 中熊秀喜1, 玉置俊治2 International Journal of Myeloma (suppl): 93-93, 2011. |
|---|
|
|
Of the examination of immunoelectrophoresis operation to support the clinical practice that P-01 is smooth there be actually it 西村精児1, 新井郁子1, 鯉堂和宏1, 高橋良一2 International Journal of Myeloma (suppl): 94-94, 2011. |
|---|
|
|
P-02 A consideration on nursing of patients who lost their children due to the disaster - Focusing on the crisis model of Aguilera and Messick - 澁谷幸子, 相内亜美, 佐藤実緒, 植木葉子, 遠藤千賀子, 書澤征子 International Journal of Myeloma (suppl): 95-95, 2011. |
|---|
